Bank of New York Mellon Corp Has $107.88 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Bank of New York Mellon Corp lowered its holdings in Sanofi (NASDAQ:SNY - Free Report) by 30.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,945,223 shares of the company's stock after selling 840,093 shares during the quarter. Bank of New York Mellon Corp owned about 0.08% of Sanofi worth $107,882,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Sanofi by 8.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company's stock valued at $7,328,000 after acquiring an additional 12,440 shares during the period. Amundi lifted its stake in shares of Sanofi by 11.1% during the fourth quarter. Amundi now owns 630,063 shares of the company's stock valued at $31,017,000 after acquiring an additional 63,195 shares during the period. Wealthfront Advisers LLC acquired a new position in shares of Sanofi during the fourth quarter valued at $1,908,000. Finally, HighTower Advisors LLC lifted its stake in shares of Sanofi by 3.4% during the fourth quarter. HighTower Advisors LLC now owns 91,071 shares of the company's stock valued at $4,392,000 after acquiring an additional 2,971 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Trading Down 1.7%

Shares of Sanofi stock traded down $0.84 during trading hours on Friday, hitting $48.50. The company's stock had a trading volume of 636,699 shares, compared to its average volume of 2,597,521. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The company has a market capitalization of $118.94 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The stock has a 50 day moving average of $50.19 and a 200 day moving average of $52.08.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. Sanofi's quarterly revenue was down 11.0% on a year-over-year basis. During the same period last year, the company earned $1.78 earnings per share. Analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a dividend of $2.0369 per share. The ex-dividend date was Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Finally, BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Three analysts have rated the stock with a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Sanofi presently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.